A review of entecavir in the treatment of chronic hepatitis B infection

Current Medical Research and Opinion

Volumn 21, Issue 11, 2005, Pages 1845-1856

  Rivkin, Anastasia ^a,b  

^a LONG ISLAND UNIVERSITY   (United States)

^b ST LUKE S ROOSEVELT HOSPITAL CENTER   (United States)

Author keywords

Chronic hepatitis B; Entecavir; HBV DNA polymerase inhibitor

Indexed keywords

ABACAVIR; ADEFOVIR DIPIVOXIL; ALPHA2B INTERFERON; DIDANOSINE; DNA POLYMERASE; ENTECAVIR; LAMIVUDINE; NUCLEOSIDE; PEGINTERFERON ALPHA2A; STAVUDINE; ZIDOVUDINE;

ABDOMINAL PAIN; CHRONIC HEPATITIS; CLINICAL TRIAL; COUGHING; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; FATIGUE; HEADACHE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; LONG TERM CARE; MEDICAL ASSESSMENT; NEPHROTOXICITY; NONHUMAN; REVIEW; RHINOPHARYNGITIS; UPPER RESPIRATORY TRACT INFECTION;

ANIMALS; CLINICAL TRIALS; GUANINE; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; LAMIVUDINE; PRACTICE GUIDELINES; RANDOMIZED CONTROLLED TRIALS; REVERSE TRANSCRIPTASE INHIBITORS; TREATMENT OUTCOME;

EID: 27944461707     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079905X65268     Document Type: Review

References (84)

1. Lai CL, Ratziu V, Yuen MF, Poynard T. Viral hepatitis B. Lancet 2003;362:2089-94
2. Lavanchy D. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepatitis 2004;11:97-107
3. Centers for Disease Control and Prevention. Updated US Public Health Service guidelines for the management of occupational exposures to HBV, HCV, and HIV and recommendations for postexposure prophylaxis. MMWR 2001;50(RR-11):1-42 〈http://www.cdc.gov/mmwr/preview/mmwrhtml/rr5011a1. htm [Last accessed 04 October 2005]〉
4. Centers for Disease Control and Prevention. Disease burden from hepatitis A, B, and C in the United States; 2005 http://www.cdc.gov/ncidod/diseases/ hepatitis/resource/dz_burden02. htm [Last accessed 04 October 2005]
5. Shaw T, Locarnini S. Entecavir for the treatment of chronic hepatitis B. Expert Rev Anti Infect Ther 2004;2:853-71
6. Lok AS, McMahon BJ. Chronic hepatitis B: update of recommendations. Hepatology 2004;39:857-61
7. Custer B, Sullivan SD, Hazlet TK, et al. Global epidemiology of hepatitis B virus. J Clin Gastroenterol 2004;38:S158-68
8. Rivkina A, Rybalov S. Chronic hepatitis B: current and future treatment options. Pharmacotherapy 2002;22:721-37
9. Arauz-Ruiz P, Norder H, Robertson BH, Magnius LO. Genotype H: a new Amerindian genotype of hepatitis B virus revealed in Central America. J Gen Virol 2002;83:2059-73
10. Bell SJ, Lau A, Thompson A, et al. Chronic hepatitis B: recommendations for therapy based on the natural history of disease in Australian patients. J Clin Virol 2005;32:122-7
11. Kidd-Ljunggren K, Miyakawa Y, Kidd AH. Genetic variability in hepatitis B viruses. J Gen Virol 2002;83:1267-80
12. Lok AS, Heathcote EJ, Hoofnagle JH. Management of hepatitis B: 2000 - summary of a workshop. Gastroenterology 2001;120:1828-53
13. Wong DK, Cheung AM, O'Rourke K, et al. Effect of alpha-interferon treatment in patients with hepatitis B e antigen-positive chronic hepatitis B. A meta-analysis. Ann Intern Med 1993;119:312-23
14. Lin SM, Sheen IS, Chien RN, et al. Long-term beneficial effect of interferon therapy in patients with chronic hepatitis B virus infection. Hepatology 1999;29:971-5
15. Lau DT, Everhart J, Kleiner DE, et al. Long-term follow-up of patients with chronic hepatitis B treated with interferon alfa. Gastroenterology 1997;113:1660-7
16. Lok AS, Chung HT, Liu VW, Ma OC. Long-term follow-up of chronic hepatitis B patients treated with interferon alfa. Gastroenterology 1993;105:1833-8
17. Krogsgaard K. The long-term effect of treatment with interferon-alpha 2a in chronic hepatitis B [The Long-Term Follow-up Investigator Group. The European Study Group on Viral Hepatitis (EUROHEP). Executive Team on Anti-Viral Treatment]. J Viral Hepatitis 1998;5:389-97
18. Piratvisuth T, Marcellin P, Lau G. ALT flares and sustained ALT response in patients with HBeAg-negative chronic hepatitis B treated with peginterferon alfa-2A(40kd), peginterferon-alfa 2A(40kd) plus lamivudine or lamivudine alone (abstract ). Hepatology 2004;40:656A
19. Bonino F, Lau G, Marcellin P. The first detailed analysis of predictors of response in HBeAg-negative chronic hepatitis B: data from multicenter, randomized, partially double-blind study of peginterferon alfa-2A(40kd) alone or in combination with lamivudine versus lamivudine alone (abstract). Hepatology 2004;40:659A
20. Marcellin P, Lau GK, Bonino F, et al. Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. New Engl J Med 2004;351:1206-17
21. Lau GK, Piratvisuth T, Luo KX, et al. Peginterferon alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. New Engl J Med 2005;352:2682-95
22. Dienstag JL, Schiff ER, Wright TL, et al. Lamivudine as initial treatment for chronic hepatitis B in the United States. New Engl J Med 1999;341:1256-63
23. Lai CL, Chien RN, Leung NW, et al. A one-year trial of lamivudine for chronic hepatitis B [Asia Hepatitis Lamivudine Study Group]. New Engl J Med 1998;339:61-8
24. Schalm SW, Heathcote J, Cianciara J, et al. Lamivudine and alpha interferon combination treatment of patients with chronic hepatitis B infection: a randomised trial. Gut 2000;46:562-8
25. Dienstag JL, Cianciara J, Karayalcin S, et al. Durability of serologic response after lamivudine treatment of chronic hepatitis B. Hepatology 2003;37:748-55
26. Song BC, Suh DJ, Lee HC, et al. Hepatitis B e antigen seroconversion after lamivudine therapy is not durable in patients with chronic hepatitis B in Korea. Hepatology 2000;32:803-6
27. Lee KM, Cho SW, Kim SW, et al. Effect of virological response on post-treatment durability of lamivudine-induced HBeAg seroconversion. J Viral Hepatitis 2002;9:208-12
28. Tassopoulos NC, Volpes R, Pastore G, et al. Efficacy of lamivudine in patients with hepatitis B e antigen-negative/hepatitis B virus DNA-positive (precore mutant) chronic hepatitis B [Lamivudine Precore Mutant Study Group]. Hepatology 1999;29:889-96
29. Hadziyannis SJ, Papatheodoridis GV, Dimou E, et al. Efficacy of long-term lamivudine monotherapy in patients with hepatitis B e antigen-negative chronic hepatitis B. Hepatology 2000;32: 847-51
30. Rizzetto M, Volpes R, Smedile A. Response of pre-core mutant chronic hepatitis B infection to lamivudine. J Med Virol 2000;61:398-402
31. Tassopoulos NC, Volpes R, Pastore G, et al. Post lamivudine treatment follow-up of patients with HBeAg negative chronic hepatitis [abstract]. J Hepatol 1999;30:117A
32. Liaw YF, Chien RN, Yeh CT, et al. Acute exacerbation and hepatitis B virus clearance after emergence of YMDD motif mutation during lamivudine therapy. Hepatology 1999;30: 567-72
33. Marcellin P, Chang TT, Lim SG, et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. New Engl J Med 2003;348:808-16
34. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B. New Engl J Med 2003;348:800-7
35. Peters M, Hann HW, Martin P, et al. Adefovir dipivoxil (ADV) alone and in combination with lamivudine (LAM) suppresses YMDD mutant hepatitis B virus replication: 48 week preliminary analysis [abstract]. Hepatology 2002;36:374A
36. Schiff E, Willems B, Leung NW, et al. Addition of adefovir to lamivudine therapy results in significant reduction in HBV DNA and serum ALT in compensated chronic hepatitis B patients with YMDD variant HBV and a reduced response to lamivudine - 52 week result [abstract]. Hepatology 2002;36:636A
37. Marcellin P, Chang TT, Lim SG, et al. Long term efficacy and safety of adefovir dipivoxil (ADV) 10mg in the HBeAg+ chronic hepatitis B (CHB) patients: increasing serologic, virologic and biochemical response over time [abstract]. Hepatology 2004;40:655A
38. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, et al. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B. New Engl J Med 2005;352:2673-81
39. Angus P, Vaughan R, Xiong S, et al. Resistance to adefovir dipivoxil therapy associated with the selection of a novel mutation in the HBV polymerase. Gastroenterology 2003;125:292-7
40. Locarnini S, Qi X, Arterburn S. Incidence and predictors of emergence of adefovir resistant HBV during four years of adefovir dipivoxil (ADV) therapy for patients with chronic hepatitis B (CHB) [abstract 36]. 40th Annual Meeting of the European Association for the Study of the Liver. Paris, France; 2005
41. Keeffe EB, Dieterich DT, Han SH, et al. A treatment algorithm for the management of chronic hepatitis B virus infection in the United States. Clin Gastroenterol Hepatol 2004;2:87-106
42. Seifer M, Hamatake RK, Colonno RJ, Standring DN. In vitro inhibition of hepadnavirus polymerases by the triphosphates of BMS-200475 and lobucavir. Antimicrob Agents Chemother 1998;42:3200-8
43. Ruediger E, Martel A, Manwel N, et al. Novel 3'-deoxy analogs of the anti-HBV agent entecavir: synthesis of enantiomers from a single chiral epoxide. Tetrahedron Lett 2004;45:739-42
44. Yamanaka G, Wilson T, Innaimo S, et al. Metabolic studies on BMS-200475, a new antiviral compound active against hepatitis B virus. Antimicrob Agents Chemother 1999;43: 190-3
45. Bifano M, Yan J, Xie J, et al. Hepatic impairment does not alter single-dose pharmacokinetics and safety of entecavir [abstract]. Hepatology 2004;40:663A
46. Baraclude TM (entecavir) package insert. Princeton (NJ): Bristol Myers Squibb Company; March 2005
47. Zoulim F. Assessing hepatitis B virus resistance in vitro and molecular mechanisms of nucleoside resistance. Semin Liver Dis 2002;22(Suppl 1):23-31
48. Tsiang M, Rooney JF, Toole JJ, Gibbs CS. Biphasic clearance kinetics of hepatitis B virus from patients during adefovir dipivoxil therapy. Hepatology 1999;29:1863-9
49. Whalley SA, Murray JM, Brown D, et al. Kinetics of acute hepatitis B virus infection in humans. J Exp Med 2001;193:847-54
50. Wolters LM, Hansen BE, Niesters HG, et al. Viral dynamics during and after entecavir therapy in patients with chronic hepatitis Br J Hepatol 2002;37:137-44
51. Innaimo SF, Seifer M, Bisacchi GS, et al. Identification of BMS-200475 as a potent and selective inhibitor of hepatitis B virus. Antimicrob Agents Chemother 1997;41:1444-8
52. Colonno RJ, Genovesi EV, Medina I, et al. Long-term entecavir treatment results in sustained antiviral efficacy and prolonged life span in the woodchuck model of chronic hepatitis infection. J Infect Dis 2001;184:1236-45
53. Genovesi EV, Lamb L, Medina I, et al. Efficacy of the carbocyclic 2'-deoxyguanosine nucleoside BMS-200475 in the woodchuck model of hepatitis B virus infection. Antimicrob Agents Chemother 1998;42:3209-17
54. Tuttleman JS, Pourcel C, Summers J. Formation of the pool of covalently closed circular viral DNA in hepadnavirus-infected cells. Cell 1986;47:451-60
55. Wu TT, Coates L, Aldrich CE, et al. In hepatocytes infected with duck hepatitis B virus, the template for viral RNA synthesis is amplified by an intracellular pathway. Virology 1990;175: 255-61
56. Dandri M, Burda MR, Will H, Petersen J. Increased hepatocyte turnover and inhibition of woodchuck hepatitis B virus replication by adefovir in vitro do not lead to reduction of the closed circular DNA. Hepatology 2000;32:139-46
57. Moraleda G, Saputelli J, Aldrich CE, et al. Lack of effect of antiviral therapy in nondividing hepatocyte cultures on the closed circular DNA of woodchuck hepatitis virus. J Virol 1997;71:9392-9
58. Marion PL, Salazar FH, Winters MA, Colonno RJ. Potent efficacy of entecavir (BMS-200475) in a duck model of hepatitis B virus replication. Antimicrob Agents Chemother 2002;46:82-8
59. Foster WK, Miller DS, Marion PL, et al. Entecavir therapy combined with DNA vaccination for persistent duck hepatitis B virus infection. Antimicrob Agents Chemother 2003;47: 2624-35
60. de Man RA, Wolters LM, Nevens F, et al. Safety and efficacy of oral entecavir given for 28 days in patients with chronic hepatitis B virus infection. Hepatology 2001;34:578-82
61. Lai CL, Rosmawati M, Lao J, et al. Entecavir is superior to lamivudine in reducing hepatitis B virus DNA in patients with chronic hepatitis B infection. Gastroenterology 2002;123: 1831-8
62. Chang TT, Hadziyannis S, Cianciara J, et al. Sustained viral load and ALT reduction following 48 weeks of entecavir treatment in subjects with chronic hepatitis B who have failed lamivudine [abstract]. Hepatology 2002;36:300A
63. Chang TT, Gish R, de Man RA, et al. Entecavir is superior to lamivudine for the treatment of HBeAg(+) chronic hepatitis B: results of phase III study ETV-022 in nucleoside-naive patients [abstract]. Hepatology 2004;40:193A
64. Rosmawati M, Schiff E, Parana R, et al. Entecavir is superior to lamivudine at reducing HBV DNA in patients with chronic hepatitis B regardless of baseline alanine aminotransferase levels [abstract]. Hepatology 2004;40:656A
65. Shouval D, Lai CL, Cheinquer H, et al. Entecavir demonstrates superior histologic and virologic efficacy over lamivudine in nucleoside-naive HBeAg(-) chronic hepatitis B: results of phase III trial ETV-027 [abstract]. Hepatology 2004;40:728A
66. Lurie Y, Manns MP, Gish R. The efficacy of entecavir is similar regardless of disease-related baseline subgroups in treatment of nucleoside-naive, HBeAg(+) and HBeAg(-) patients with chronic hepatitis B [abstract 509]. 40th Annual Meeting of the European Association for the Study of the Liver. Paris, France; 2005
67. Sherman M, Yurdaydin C, Sollano J, et al. Entecavir is superior to continued lamivudine for the treatment of lamivudine-refractory, HBeAg(+) chronic hepatitis B: results of phase III study ETV-026 [abstract]. Hepatology 2004;40:664A
68. Gish R, de Man RA, Pedersen C. Sustained response off-treatment to entecavir and lamivudine after 48 weeks of treatment in nucleoside-naive, HBeAg(+) patients: 24-week follow-up results of phase 3 study ETV-022 [abstract 490]. 40th Annual Meeting of the European Association for the Study of the Liver. Paris, France; 2005
69. Tenney DJ, Levine SM, Rose RE, et al. Clinical emergence of entecavir-resistant hepatitis B virus requires additional substitutions in virus already resistant to lamivudine. Antimicrob Agents Chemother 2004;48:3498-507
70. Allen MI, Deslauriers M, Andrews CW, et al. Identification and characterization of mutations in hepatitis B virus resistant to lamivudine [Lamivudine Clinical Investigation Group]. Hepatology 1998;27:1670-7
71. Villeneuve JP, Durantel D, Durantel S, et al. Selection of a hepatitis B virus strain resistant to adefovir in a liver transplantation patient. J Hepatol 2003;39:1085-9
72. Levine S, Hernandez D, Yamanaka G, et al. Efficacies of entecavir against lamivudine-resistant hepatitis B virus replication and recombinant polymerases in vitro. Antimicrob Agents Chemother 2002;46:2525-32
73. Tenney DJ, Langley DR, Oliver AJ, et al. Hepatitis B virus resistance to entecavir involves novel changes in the viral polymerase [abstract 184]. Hepatology 2004;40:245A
74. Colonno RJ, Rose R, Levine SM, et al. Emergence of entecavir resistant hepatitis B virus after one year of therapy in phase II & III studies is only observed in lamivudine refractory patients [abstract]. Hepatology 2004;40:661A
75. Honkoop P, De Man RA. Entecavir: a potent new antiviral drug for hepatitis B. Expert Opin Invest Drugs 2003;12:683-8
76. Sollano J, Schiff E, Carrilho F, et al. Entecavir is well-tolerated for treatment of chronic hepatitis B: phase III safety analysis in nucleoside-naive and lamivudine-refractory patients [abstract]. Hepatology 2004;40:665A
77. Colonno RJ, Discotto L, Gong YF, et al. Combination studies involving entecavir and HIV nucleoside reverse transcriptase inhibitors showed no antagonistic effects on HBV or HIV activity in vitro [abstract]. J Hepatol 2004;40(Suppl 1):110
78. Ying C, De Clerq E, Colonno RJ, Neyts J. Ribavirin and mycophenolic acid potentiate the activity of entecavir against hepatitis B virus [abstract]. Antiviral Res 2004;62:A47
79. Feld J, Locarnini S. Antiviral therapy for hepatitis B virus infections: new targets and technical challenges. J Clin Virol 2002;25:267-83
80. Akarca US, Ersoz G, Gunsar F, et al. Interferon-lamivudine combination is no better than lamivudine alone in anti-HBe-positive chronic hepatitis B. Antiviral Ther 2004;9:325-34
81. Janssen HL, van Zonneveld M, Senturk H, et al. Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial. Lancet 2005;365:123-9
82. Peters MG, Hann Hw H, Martin P, et al. Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B. Gastroenterology 2004;126: 91-101
83. Sung J, Lai CL, Zeuzem S, et al. A randomized double blind Phase II study of lamivudine compared to lamivudine plus adefovir dipivoxil for treatment-naive patients with chronic hepatitis B [oral presentation]. 38th Annual Meeting of the European Association for the Study of the Liver. Istanbul, Turkey; 2003
84. Delaney WEt, Yang H, Miller MD, et al. Combinations of adefovir with nucleoside analogs produce additive antiviral effects against hepatitis B virus in vitro. Antimicrob Agents Chemother 2004;48:3702-10